AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

This study is testing the safety and effects of a new investigational drug called AMX0114 in people with ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), a progressive disease that damages nerve cells controlling muscle movement. **You may be eligible if...** - You are 18 or older - You have been diagnosed with clinically definite or clinically probable ALS by an experienced specialist - Your first ALS symptom (muscle weakness) began less than 24 months ago - If you are taking riluzole or edaravone (standard ALS treatments), you have been on a stable dose for at least 30 days - You agree to use contraception during the study if you could become pregnant or father a child **You may NOT be eligible if...** - You have had ALS symptoms for more than 24 months - You have serious organ function problems unrelated to ALS - You are pregnant or planning to become pregnant during the trial - Your disease is too advanced for the treatment to be safely administered Talk to your doctor to see if this trial is right for you.